Neurocrine Biosciences (NBIX) Free Cash Flow Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 10.34% |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -43.16% |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | -12.44% |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 152.68% |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 44.93% |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -291.47% |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 24.53% |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 49.78% |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn | 250.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 152.68% |
| Dec 31, 2025 | 50.94% |
| Sep 30, 2025 | 66.84% |
| Jun 30, 2025 | 108.62% |
| Mar 31, 2025 | -58.13% |
| Dec 31, 2024 | 144.75% |
| Sep 30, 2024 | -33.79% |
| Jun 30, 2024 | -73.98% |
| Mar 31, 2024 | 202.70% |
| Dec 31, 2023 | -24.45% |
| Sep 30, 2023 | 97.73% |
| Jun 30, 2023 | 27.53% |
| Mar 31, 2023 | -161.54% |
| Dec 31, 2022 | 657.14% |
| Sep 30, 2022 | 131.31% |
| Jun 30, 2022 | 22.56% |
| Mar 31, 2022 | -158.09% |
| Dec 31, 2021 | -83.12% |
| Sep 30, 2021 | 291.12% |
| Jun 30, 2021 | -11.57% |